[go: up one dir, main page]

MA45665B1 - Dérivés d'éthynyle - Google Patents

Dérivés d'éthynyle

Info

Publication number
MA45665B1
MA45665B1 MA45665A MA45665A MA45665B1 MA 45665 B1 MA45665 B1 MA 45665B1 MA 45665 A MA45665 A MA 45665A MA 45665 A MA45665 A MA 45665A MA 45665 B1 MA45665 B1 MA 45665B1
Authority
MA
Morocco
Prior art keywords
compounds
ethynyl derivatives
neuroprotection
autism
obsessive
Prior art date
Application number
MA45665A
Other languages
English (en)
Inventor
Daniel Rueher
Georg Jaeschke
Antonio Ricci
Barbara Biemans
Fionn O`Hara
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA45665B1 publication Critical patent/MA45665B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formules ia et ib ia ib ou à un sel pharmaceutiquement accepté ou un sel d'addition acide, à un mélange racémique, ou à son énantiomère correspondant et/ou isomère optique et/ou stéréoisomère de celui-ci. Les composés peuvent être utilisés pour le traitement de la maladie de parkinson, de l'anxiété, des vomissements, d'un trouble obsessionnel compulsif, de l'autisme, la neuroprotection, du cancer, de la dépression et du diabète de type 2.
MA45665A 2016-07-18 2017-07-12 Dérivés d'éthynyle MA45665B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16179837 2016-07-18
PCT/EP2017/067495 WO2018015235A1 (fr) 2016-07-18 2017-07-12 Dérivés d'éthynyle

Publications (1)

Publication Number Publication Date
MA45665B1 true MA45665B1 (fr) 2020-11-30

Family

ID=56418435

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45665A MA45665B1 (fr) 2016-07-18 2017-07-12 Dérivés d'éthynyle

Country Status (31)

Country Link
US (3) US20190144458A1 (fr)
EP (1) EP3484889B1 (fr)
JP (1) JP6936305B2 (fr)
KR (1) KR20190026805A (fr)
CN (1) CN109476671B (fr)
AR (1) AR109075A1 (fr)
AU (1) AU2017299083B2 (fr)
BR (1) BR112019000314A2 (fr)
CA (1) CA3030788A1 (fr)
CL (1) CL2019000045A1 (fr)
CO (1) CO2018013824A2 (fr)
CR (1) CR20190014A (fr)
DK (1) DK3484889T3 (fr)
ES (1) ES2826389T3 (fr)
HR (1) HRP20201615T1 (fr)
HU (1) HUE051006T2 (fr)
IL (1) IL263884A (fr)
LT (1) LT3484889T (fr)
MA (1) MA45665B1 (fr)
MX (1) MX376249B (fr)
PE (1) PE20190382A1 (fr)
PH (1) PH12019500119A1 (fr)
PL (1) PL3484889T3 (fr)
PT (1) PT3484889T (fr)
RS (1) RS60908B1 (fr)
RU (1) RU2745068C2 (fr)
SG (1) SG11201811829QA (fr)
SI (1) SI3484889T1 (fr)
TW (1) TWI729169B (fr)
WO (1) WO2018015235A1 (fr)
ZA (1) ZA201900113B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42442B1 (fr) 2015-07-15 2019-07-31 Hoffmann La Roche Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
CN110183456A (zh) * 2019-07-11 2019-08-30 河南师范大学 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法
US11515154B2 (en) * 2020-10-27 2022-11-29 Applied Materials, Inc. Selective deposition of a passivation film

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569915A4 (fr) * 2002-12-04 2007-07-11 Merck & Co Inc Urees spirocycliques, compositions les contenant et procedes d'utilisation
EP1891075B1 (fr) 2005-05-24 2011-10-19 Merck Serono SA Derives spiro tricycliques servant de modulateurs de crth2
US7998961B2 (en) 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents
MX2009013169A (es) 2007-06-03 2010-04-30 Univ Vanderbilt Moduladores alostericos positivos del mglur5 benzamida y metodos de elaboracion y uso de los mismos.
BR112012004919A2 (pt) 2009-09-04 2019-09-24 Univ Vanderbilt potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
PL2702051T3 (pl) 2011-04-26 2015-08-31 Hoffmann La Roche Pochodne etynylu jako pozytywne allosteryczne modulatory mglur5
PH12013501928A1 (en) 2011-04-26 2013-11-25 Hoffmann La Roche Pyrazolidin-3-one derivatives
CA2837312A1 (fr) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees
ES2553449T3 (es) * 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
ES2600133T3 (es) 2012-07-17 2017-02-07 F. Hoffmann-La Roche Ag Derivados de ariletinilo
MY171517A (en) 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
UA114934C2 (uk) 2012-10-18 2017-08-28 Ф. Хоффманн-Ля Рош Аг Похідне етинілу як модулятор активності метаботропного глутаматного рецептора підтипу 5
WO2014124560A1 (fr) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Régulateurs de mglur
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
PL3049409T3 (pl) * 2013-09-25 2017-09-29 F.Hoffmann-La Roche Ag Pochodne etynylowe
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
EA029261B1 (ru) 2014-02-25 2018-02-28 Ф. Хоффманн-Ля Рош Аг Производные этинила
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN107207481B (zh) 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
MA42442B1 (fr) * 2015-07-15 2019-07-31 Hoffmann La Roche Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
US10391998B2 (en) 2016-11-16 2019-08-27 Ford Global Technologies, Llc Vehicle systems and methods for reducing electrified vehicle noise, vibration, and harshness

Also Published As

Publication number Publication date
DK3484889T3 (da) 2020-10-26
MX2019000442A (es) 2019-06-20
CR20190014A (es) 2019-03-04
SI3484889T1 (sl) 2020-11-30
PL3484889T3 (pl) 2020-12-28
RU2745068C2 (ru) 2021-03-18
EP3484889A1 (fr) 2019-05-22
JP6936305B2 (ja) 2021-09-15
TWI729169B (zh) 2021-06-01
CN109476671A (zh) 2019-03-15
RU2019102757A (ru) 2020-08-18
CO2018013824A2 (es) 2018-12-28
PT3484889T (pt) 2020-10-15
AU2017299083A1 (en) 2019-01-24
CN109476671B (zh) 2021-09-24
RS60908B1 (sr) 2020-11-30
JP2019521158A (ja) 2019-07-25
CL2019000045A1 (es) 2019-06-07
PH12019500119A1 (en) 2019-12-11
HRP20201615T1 (hr) 2020-12-11
US20220127275A1 (en) 2022-04-28
LT3484889T (lt) 2020-11-10
BR112019000314A2 (pt) 2019-04-16
ES2826389T3 (es) 2021-05-18
SG11201811829QA (en) 2019-02-27
AU2017299083B2 (en) 2021-06-24
US20190144458A1 (en) 2019-05-16
MX376249B (es) 2025-03-07
TW201805287A (zh) 2018-02-16
AR109075A1 (es) 2018-10-24
ZA201900113B (en) 2019-09-25
US12145940B2 (en) 2024-11-19
KR20190026805A (ko) 2019-03-13
WO2018015235A1 (fr) 2018-01-25
HUE051006T2 (hu) 2021-01-28
IL263884A (en) 2019-01-31
RU2019102757A3 (fr) 2020-08-18
EP3484889B1 (fr) 2020-08-19
US20200255440A1 (en) 2020-08-13
CA3030788A1 (fr) 2018-01-25
PE20190382A1 (es) 2019-03-08
US11242349B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
MA42442B1 (fr) Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
RU2471781C2 (ru) Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии
MA51530B1 (fr) Composés cycliques fondus
MA47368B1 (fr) N-[4-fluoro-5-[[(2s,4s)-2-méthyl-4-[(5-méthyl-1,2,4-oxadiazol-3-yl)méthoxy]-1-pipéridyl]méthyl]thiazol-2-yl]acétamide utilisés en tant qu'inhibiteur d'oga
MA40993A (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
WO2019007696A1 (fr) Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
PH12016501100A1 (en) Ethynyl-imidazolin-2, 4-dione derivatives as mglur4 modulators
MA45665B1 (fr) Dérivés d'éthynyle
MA43256B1 (fr) Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA43706B1 (fr) Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité en tant qu'agoniste de taar
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
MA52482B1 (fr) Dérivés de spiropipéridine en tant que modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA54447B1 (fr) Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés similaires en tant que modulateurs de la secretase gamma pour le traitement de la maladie d'alzheimer
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
MA38011B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5
MA60976B1 (fr) Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine
MA53258A (fr) Composés pour le traitement de la maladie d'alzheimer
MA50036B1 (fr) Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht6
FR3073842B1 (fr) Procede de preparation du 1-chloro-3,3,3-trifluoropropene
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
TH170900A (th) สารอนุพันธ์เอไธนิล-อิมิดาโซลิน-2,4-ไดโอน ในฐานะเป็นตัวคุม mGluR4